OBSERVATIONAL STUDY COMPARING TREATMENT PERSISTENCE IN BIOLOGIC NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR ETANERCEPT

被引：0
|
作者：
Clancy, Z. [1 ]
Tencer, T. [1 ]
Kaura, S. [1 ]
Li, S. [1 ]
机构：
[1] Celgene Corp, Summit, NJ USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS21
引用
收藏
页码：A159 / A159
页数：1
相关论文
共 50 条
  • [31] Treatment Persistence and Safety of Apremilast in Psoriasis: Experience With 30 Patients in Routine Clinical Practice
    Sahuquillo-Torralba, A.
    de Unamuno Bustos, B.
    Rodriguez Serna, M.
    Monte Boquet, E.
    Botella Estrada, R.
    [J]. ACTAS DERMO-SIFILIOGRAFICAS, 2020, 111 (05): : 415 - 418
  • [32] Apremilast for biologic-naive, peripheral psoriatic arthritis, including patients with early disease: results from the APROACH observational prospective study
    Sfikakis, Petros P.
    Vassilopoulos, Dimitrios
    Katsifis, Gkikas
    Vosvotekas, Georgios
    Dimitroulas, Theodoros
    Sidiropoulos, Prodromos
    Vounotrypidis, Periklis
    Bogdanos, Dimitrios P.
    Georgountzos, Athanasios, I
    Bounas, Andreas G.
    Georgiou, Panagiotis
    Gazi, Souzana
    Kataxaki, Evangelia
    Liossis, Stamatis-Nick
    Theodorou, Evangelos
    Papagoras, Charalampos
    Theotikos, Evangelos
    Vlachoyiannopoulos, Panayiotis
    Voulgari, Paraskevi V.
    Kekki, Angeliki
    Antonakopoulos, Nikolaos
    Boumpas, Dimitrios T.
    [J]. RHEUMATOLOGY INTERNATIONAL, 2023, 43 (5) : 889 - 902
  • [33] REAL-WORLD COST PER PERSISTING PATIENT: COMPARING PSORIASIS PATIENTS INITIATED ON APREMILAST OR BIOLOGIC THERAPIES
    Feldman, S. R.
    Kuznik, A.
    Clancy, Z.
    [J]. VALUE IN HEALTH, 2016, 19 (03) : A125 - A125
  • [34] REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
    Kaplan, D.
    Ung, B.
    Udeze, C.
    Pelletier, C.
    Tian, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S888 - S888
  • [35] Persistence of biologic therapy in psoriasis patients with comorbidity
    Jacobi, Arnd
    Rustenbach, Stephan J.
    Augustin, Matthias
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB262 - AB262
  • [36] Considerations When Initiating Psoriasis Patients on Biologic Therapy
    Zeichner, Joshua A.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2012, 11 (05) : S11 - S14
  • [37] LIBERATE trial: sustained efficacy of apremilast in patients with moderate-to-severe psoriasis who continued on apremilast or switched from etanercept treatment
    Reich, K.
    Soung, J.
    Gooderham, M.
    Zhang, Z.
    Nograles, K.
    Goodfield, M.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2016, 175 : 71 - 72
  • [38] CHANGE IN PERSISTENCE OVER TIME OF BIOLOGIC THERAPIES FOR THE TREATMENT OF PLAQUE PSORIASIS - A NATIONAL OBSERVATIONAL LONGITUDINAL POPULATION STUDY IN SWEDEN
    Stelmaszuk-Zadykowicz, N. M.
    Apol, E.
    Hansen, J. B.
    Freilich, J.
    [J]. VALUE IN HEALTH, 2019, 22 : S434 - S434
  • [39] Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
    Tanaka, Masayuki
    Ozeki, Yasushi
    Matsuyama, Fujio
    Murata, Tatsunori
    Imafuku, Shinichi
    Nakamura, Taichi
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (02) : 451 - 466
  • [40] Apremilast Prolongs the Time to First Biologic Therapy in Japanese Patients with Psoriasis
    Masayuki Tanaka
    Yasushi Ozeki
    Fujio Matsuyama
    Tatsunori Murata
    Shinichi Imafuku
    Taichi Nakamura
    [J]. Dermatology and Therapy, 2022, 12 : 451 - 466
12345